Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
XVIVO’s clinically proven machine perfusion technologies and solutions are used globally to preserve, transport, and assess organs outside the body. Their products have increased utilization of donated organs and improved transplant outcomes. The company has presented positive clinical results from multicenter heart transplantation trials as recently as April 2025.
PERFADEX Plus solution is used by more than 90% of all lung transplant clinics worldwide.
The company has at least four clinical trials completed or ongoing.
Recent news includes a successful European multicenter heart transplantation trial with positive follow-up results presented at ISHLT in Boston in April 2025.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on XVIVO Perfusion.